1. Home
  2. LPG vs NUVB Comparison

LPG vs NUVB Comparison

Compare LPG & NUVB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Dorian LPG Ltd.

LPG

Dorian LPG Ltd.

HOLD

Current Price

$29.06

Market Cap

1.5B

ML Signal

HOLD

NUVB

Nuvation Bio Inc.

HOLD

Current Price

$4.46

Market Cap

1.6B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
LPG
NUVB
Founded
2013
2018
Country
United States
United States
Employees
N/A
291
Industry
Marine Transportation
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
1.5B
1.6B
IPO Year
2014
N/A

Fundamental Metrics

Financial Performance
Metric
LPG
NUVB
Price
$29.06
$4.46
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
1
9
Target Price
$35.00
$11.22
AVG Volume (30 Days)
559.1K
4.7M
Earning Date
05-04-2026
01-01-0001
Dividend Yield
10.67%
N/A
EPS Growth
N/A
N/A
EPS
2.64
N/A
Revenue
$353,341,476.00
N/A
Revenue This Year
$33.36
$182.76
Revenue Next Year
N/A
$91.83
P/E Ratio
$11.36
N/A
Revenue Growth
N/A
N/A
52 Week Low
$16.66
$1.57
52 Week High
$38.40
$9.75

Technical Indicators

Market Signals
Indicator
LPG
NUVB
Relative Strength Index (RSI) 34.73 34.56
Support Level $24.21 $4.04
Resistance Level $29.62 $5.73
Average True Range (ATR) 1.30 0.32
MACD -1.03 -0.04
Stochastic Oscillator 1.37 16.38

Price Performance

Historical Comparison
LPG
NUVB

About LPG Dorian LPG Ltd.

Dorian LPG Ltd is an international liquefied petroleum gas shipping company focused on owning and operating gas carriers, or VLGCs. The company currently owns and operates around 22 modern VLGCs, including nineteen new fuel-efficient 84,000 cbm ECO-design VLGCs. Dorian LPG has offices in Connecticut, USA, London, United Kingdom, and Athens, Greece. IT operates in one reportable segment, the international transportation of LPG.

About NUVB Nuvation Bio Inc.

Nuvation Bio Inc is a biopharmaceutical company tackling unmet needs in oncology by developing differentiated and novel therapeutic candidates. Its product candidate, taletrectinib, is an oral, potent, central nervous system-active, selective, next-generation c-ros oncogene 1 (ROS1) inhibitor designed for the treatment of patients with ROS1+ non-small cell lung cancer (NSCLC). In addition, its clinical-stage pipeline includes oncology product candidates such as Safusidenib, NUV-1511, and NUV-868 in different stages of development. The Company generates revenue from out-licensing collaborative agreements, including product revenue, upfront license fees, royalty revenue, and research and development services revenue. The Company generates the majority of its revenue from Japan.

Share on Social Networks: